Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
13,253 total articles
Cabot Corporation's Board of Directors declared a 5% increase in its quarterly dividend to $0.4725 per share, payable June 12, 2026. The raise highlights confidence in the company's strong cash flow, liquidity, and earnings durability, while maintaining investment capacity and a flexible balance sheet.
BioAge Labs, a clinical-stage biopharmaceutical company, will host an R&D Day webcast on May 8, 2026, presenting Phase 1 clinical data and the development rationale for BGE-102, a novel NLRP3 inflammasome inhibitor. The presentation includes insights from leading experts on NLRP3 biology and potential treatments for atherosclerotic cardiovascular d…
Unitil Corporation announced a net income of $33.2 million, or $1.85 EPS, for Q1 2026, reflecting a $5.7 million increase from Q1 2025. Adjusted net income, excluding transaction costs related to recent acquisitions, was $33.8 million or $1.88 EPS. The company experienced higher electric and gas gross margins driven by rate increases, customer grow…
Opus Genetics announced that its investigational gene therapy OPGx-LCA5 for Leber congenital amaurosis type 5 (LCA5), a rare inherited retinal disease, has been accepted into the FDA's Rare Disease Evidence Principles (RDEP) program. This acceptance supports collaboration with the FDA on regulatory strategy and clinical trial design, potentially ac…
Microvast Holdings, Inc., a leading developer of advanced battery technologies for electric vehicles and energy storage, announced it will release its Q1 2026 financial results after market close on May 11, 2026. A webcast and earnings call will follow to discuss business results and outlook. The company highlighted its 19-year legacy and extensive…
CRISPR Therapeutics AG reported its Q1 2026 financial results, highlighting $43 million in CASGEVY sales and ongoing expansion in approved markets. The company is progressing multiple clinical trials across autoimmune diseases, in vivo liver editing, and siRNA programs targeting major cardiovascular and immuno-oncology indications. Cash reserves in…
Cellectis, a clinical-stage biotech company specializing in gene editing and allogeneic CAR T immunotherapies, will report its Q1 2026 financial results on May 11, 2026 after US market close. The company will not host a conference call but remains available for investor inquiries.
Vornado Realty Trust announced its financial results for the first quarter ended March 31, 2026, reporting a net loss attributable to common shareholders of $22.8 million versus net income of $86.8 million in the prior year quarter. Funds From Operations (FFO) per share decreased to $0.49 from $0.67 in the prior year. The company continued active r…
Phoenix Asia Holdings Limited (NASDAQ: PHOE), primarily engaged in substructure works in Hong Kong, announced it has entered into a definitive Stock Acquisition Agreement to acquire 100% of ACEA Pharma, a clinical stage pharmaceutical company focused on cancer, autoimmune diseases, and Covid-19. Concurrently, the company issued a $20 million conver…
Great Elm Capital Corp. announced its first quarter 2026 financial results, highlighting a 13% increase in net investment income per share quarter-over-quarter, a strong liquidity position, and full redemption of notes due in June 2026. Jason Reese was appointed CEO, and the investment adviser waived accrued incentive fees to align interests with s…
CooperCompanies, a Nasdaq-listed global medical device company, announced the appointment of Paul Keel, an experienced CEO in the medical device sector, to its Board of Directors effective July 1, 2026. Mr. Keel will also join the Audit Committee. His leadership experience is expected to support CooperCompanies' strategic growth and value creation.
FreightCar America, Inc. reported first quarter 2026 results with revenues of $64.3 million, gross margin expansion to 16.8%, and a backlog growth to 2,058 units worth $156 million. Despite a decrease in railcar deliveries compared to the prior year, the company achieved its highest quarterly gross margin in over ten years, driven by growth in afte…
Brazil Potash Corp. (NYSE American: GRO) announced the closing of its underwritten public offering, raising approximately $63.3 million through the sale of common shares and pre-funded warrants. The proceeds will be used for working capital and general corporate purposes to support development of the Autazes potash project in Amazonas, Brazil. The …
AnaptysBio, a Nasdaq-listed biotechnology company, announced that its president and CEO, Daniel Faga, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference. The company's main focus is managing financial collaborations related to its drug royalties, notably Jemperli with GSK and imsidolimab with Va…
Fabrinet, a key provider of advanced optical packaging and manufacturing services, announced record financial results for Q3 FY2026, with revenue rising to $1.21 billion and net income per diluted share increasing to $3.45 (GAAP) and $3.72 (non-GAAP). The company exceeded its guidance ranges, driven by ongoing and ramping customer programs, and ant…
The Macerich Company declared a quarterly cash dividend of $0.17 per share payable on June 29, 2026, to shareholders of record as of June 15, 2026. Macerich is a leading U.S.-based real estate investment trust focused on retail properties in key high-density markets.
Caliber, a Nasdaq-listed real estate and digital asset management firm, will release its Q1 2026 financial results on May 13, 2026, followed by a conference call to discuss the results. The company has integrated blockchain and tokenization strategies into its platform, aiming to enhance asset financing and ownership.
Powell Industries announced its second quarter Fiscal 2026 results, highlighting a 6% revenue increase to $297 million, a record backlog of $1.8 billion, and new orders nearly doubling year-over-year to $490 million. Net income remained stable at $45.9 million despite higher expenses. Post-quarter, the company secured its largest-ever $400 million …
Firefly Aerospace announced strong first quarter 2026 financial results with record revenue of $80.9 million, a 40% increase from the previous quarter. The company secured significant contracts with the U.S. Space Force including the space-based interceptor program under Golden Dome and an engineering change proposal valued at $109 million. Firefly…
3 E Network Technology Group Limited has entered into a Securities Purchase Agreement with an institutional investor to issue a senior secured 8% original issue discount convertible promissory note amounting up to $1.3 million and warrants to purchase shares. The financing aims to support the company's transition toward becoming a next-generation A…
Adeia Inc., a technology and IP licensing company serving the semiconductor and media industries, announced that CEO Paul Davis will step down by the fourth quarter of 2026 to focus on health and personal pursuits. Davis will remain in position until a successor is named. The Board has launched a search led by a transition committee, supported by a…
ThredUp Inc. reported a 15% YoY revenue increase to $81.7 million in Q1 2026, with record active buyers growing 25% to 1.71 million. The company improved gross margin slightly to 79.2% and adjusted EBITDA margin to 3.4%. Despite a net loss, ThredUp raised its full-year 2026 revenue, gross margin, and adjusted EBITDA margin guidance, signaling confi…
Lexicon Pharmaceuticals has entered into a $100 million loan facility agreement with Hercules Capital, providing non-dilutive capital to enhance financial flexibility. The loan includes an initial $55 million tranche used to repay existing debt, with additional tranches contingent upon clinical and financial milestones. Funds will support regulator…
Capricor Therapeutics, a biotech firm specializing in cell and exosome-based therapies for rare diseases, will release its Q1 2026 financial results on May 12, 2026, followed by a conference call and webcast. The company highlighted its lead candidate, Deramiocel, targeting Duchenne muscular dystrophy, and discussed its proprietary StealthX platfor…
Kyntra Bio, a biopharmaceutical company focused on oncology and rare diseases, will report its first quarter 2026 financial results on May 11, 2026, followed by a conference call with investors. The company is advancing multiple drug candidates including Roxadustat, approved in several countries for anemia related to chronic kidney disease, and FG-…
